Ignite Creation Date:
2025-12-25 @ 5:08 AM
Ignite Modification Date:
2025-12-26 @ 4:12 AM
Study NCT ID:
NCT05067127
Status:
COMPLETED
Last Update Posted:
2025-08-06
First Post:
2021-09-23
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2025-07-17', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D015432', 'term': 'Glomerulonephritis, Membranoproliferative'}], 'ancestors': [{'id': 'D005921', 'term': 'Glomerulonephritis'}, {'id': 'D009393', 'term': 'Nephritis'}, {'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000716074', 'term': 'pegcetacoplan'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'clinicaltrials@apellis.com', 'phone': '1-833-284-6361', 'title': 'Apellis Clinical Trial Information Line', 'organization': 'Apellis Pharmaceuticals, Inc'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'TEAE data is reported from first dose of study drug (Day 1) up to 56 days after the last dose of study drug (Week 52), up to 60 weeks. All-cause mortality: From first dose of study drug (Day 1) up to end of the study, approximately 137 weeks.', 'description': 'The safety set included all subjects who received at least 1 dose of study drug.', 'eventGroups': [{'id': 'EG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.', 'otherNumAtRisk': 63, 'deathsNumAtRisk': 63, 'otherNumAffected': 53, 'seriousNumAtRisk': 63, 'deathsNumAffected': 1, 'seriousNumAffected': 6}, {'id': 'EG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.', 'otherNumAtRisk': 61, 'deathsNumAtRisk': 61, 'otherNumAffected': 56, 'seriousNumAtRisk': 61, 'deathsNumAffected': 0, 'seriousNumAffected': 6}, {'id': 'EG002', 'title': 'Open-Label Period: Pegcetacoplan to Pegcetacoplan', 'description': 'All eligible adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg who received pegcetacoplan in RCP continued to receive pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in OLP.\n\nEligible adolescent subjects with body weight 35 to \\<50 kg who received pegcetacoplan in RCP continued to receive pegcetacoplan 810 mg SC infusion twice weekly for 26 weeks in OLP.\n\nEligible adolescent subjects with body weight 30 to \\<35 kg who received pegcetacoplan in RCP continued to receive pegcetacoplan 648 mg SC infusion twice weekly for 26 weeks in OLP.', 'otherNumAtRisk': 61, 'deathsNumAtRisk': 61, 'otherNumAffected': 47, 'seriousNumAtRisk': 61, 'deathsNumAffected': 0, 'seriousNumAffected': 6}, {'id': 'EG003', 'title': 'Open-Label Period: Placebo to Pegcetacoplan', 'description': 'All eligible adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg who received placebo in RCP entered OLP to receive pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in OLP.\n\nEligible adolescent subjects with body weight 35 to \\<50 kg who received placebo in RCP entered OLP to receive pegcetacoplan 810 mg SC infusion twice weekly for 26 weeks in OLP.\n\nEligible adolescent subjects with body weight 30 to \\<35 kg who received placebo in RCP entered OLP to receive pegcetacoplan 648 mg SC infusion twice weekly for 26 weeks in OLP.', 'otherNumAtRisk': 57, 'deathsNumAtRisk': 57, 'otherNumAffected': 42, 'seriousNumAtRisk': 57, 'deathsNumAffected': 0, 'seriousNumAffected': 4}], 'otherEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 6, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 9, 'numAffected': 8}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 8, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 10, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 7, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 13, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 10, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 3, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Infusion site erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 54, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Infusion site pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 3, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Infusion site swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Injection site pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 11, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Injection site swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 33, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 48, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 44, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 22, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 14, 'numAffected': 12}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 7, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'COVID-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 15, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 9, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 20, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 14, 'numAffected': 11}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 7, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 8, 'numAffected': 7}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Acne', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 5, 'numAffected': 3}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}], 'seriousEvents': [{'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'COVID-19 pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Herpes zoster meningoencephalitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Pneumonia pneumococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Shunt infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Viral infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Maternal exposure during pregnancy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Post procedural haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Shunt malfunction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Shunt thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Blood creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Abortion spontaneous', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Pregnancy, puerperium and perinatal conditions', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Acute kidney injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'End stage renal disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Nephrotic syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Renal failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Renal impairment', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Tubulointerstitial nephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}, {'term': 'Hypertensive urgency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 57, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 26.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Randomized Controlled Period: Change From Baseline in Log-Transformed Urine Protein-to-Creatinine Ratio (uPCR) at Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'OG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.114', 'groupId': 'OG000', 'lowerLimit': '-1.380', 'upperLimit': '-0.848'}, {'value': '0.029', 'groupId': 'OG001', 'lowerLimit': '-0.090', 'upperLimit': '0.148'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in least squares (LS) mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.143', 'ciLowerLimit': '-1.436', 'ciUpperLimit': '-0.85', 'groupDescription': 'An mixed-effect model for repeated measures (MMRM) including fixed categorical effect for treatment group, visit, disease type, baseline immunosuppressants use, stratification factors, and the visit-by-treatment group interactions as well as the continuous, fixed covariate of baseline log-transformed uPCR, was utilized to analyze the log-transformed ratio of uPCR at Week 26 compared to baseline.', 'statisticalMethod': 'MMRM', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline (Day -70 to Day 1) to Week 26', 'description': 'Baseline uPCR value was calculated as the average of the uPCR measurements from at least 6 of the 9 first-morning spot urine (FMU) samples collected between the start of screening and Day 1, inclusive. The uPCR values used to calculate baseline included those from the samples collected on Day -2, Day -1, and before dosing on Day 1. In situations where less than 6 samples or more than 9 samples were collected, the average of all collected samples was used for baseline derivation. The difference between treatment groups using a composite contrast of equal-weighted average over Weeks 24, 25, and 26 was estimated.', 'unitOfMeasure': 'log (uPCR)', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITT analysis set included all randomized subjects.'}, {'type': 'SECONDARY', 'title': 'Randomized Controlled Period: Percentage of Subjects Who Achieved the Composite Renal Endpoint at Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'OG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}], 'classes': [{'categories': [{'measurements': [{'value': '49.21', 'groupId': 'OG000'}, {'value': '3.28', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '27.516', 'ciLowerLimit': '6.105', 'ciUpperLimit': '124.026', 'groupDescription': 'The logistic model included treatment group as independent variable and adjusted for baseline eGFR values, baseline log-transformed uPCR values, disease type, and stratification factors.', 'statisticalMethod': 'Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 26', 'description': 'Subject who achieved a composite renal endpoint was defined as: (1) a stable or improved estimated glomerular filtration rate (eGFR) compared to baseline (\\<=15% reduction in eGFR), and (2) a \\>=50% reduction in uPCR compared to baseline. Percentages are rounded off to the hundredth decimal place.', 'unitOfMeasure': 'percentage of subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITT analysis set included all randomized subjects.'}, {'type': 'SECONDARY', 'title': 'Randomized Controlled Period: Percentage of Subjects With a Reduction of At Least 50% From Baseline in Urine Protein-to-Creatinine Ratio at Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'OG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}], 'classes': [{'categories': [{'measurements': [{'value': '60.32', 'groupId': 'OG000'}, {'value': '4.92', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '30.932', 'ciLowerLimit': '8.401', 'ciUpperLimit': '113.897', 'groupDescription': 'The logistic model included treatment group as independent variable and adjusted for baseline log-transformed uPCR values, disease type, and stratification factors.', 'statisticalMethod': 'Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline (Day -70 to Day 1) and Week 26', 'description': 'Baseline uPCR value was calculated as the average of the uPCR measurements from at least 6 of the 9 FMU samples collected between the start of screening and Day 1, inclusive. The uPCR values used to calculate baseline included those from the samples collected on Day -2, Day -1, and before dosing on Day 1. In situations where less than 6 samples or more than 9 samples were collected, the average of all collected samples was used for baseline derivation. Percentages are rounded off to the hundredth decimal place.', 'unitOfMeasure': 'percentage of subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITT analysis set included all randomized subjects.'}, {'type': 'SECONDARY', 'title': 'Randomized Controlled Period: Change From Baseline in the C3 Glomerulopathy (C3G) Histologic Index Activity Score at Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'OG000'}, {'value': '34', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'OG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}], 'classes': [{'categories': [{'measurements': [{'value': '-3.482', 'groupId': 'OG000', 'lowerLimit': '-4.721', 'upperLimit': '-2.244'}, {'value': '-2.480', 'groupId': 'OG001', 'lowerLimit': '-3.775', 'upperLimit': '-1.186'}]}]}], 'analyses': [{'pValue': '0.2753', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in LS mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.002', 'ciLowerLimit': '-2.803', 'ciUpperLimit': '0.798', 'groupDescription': 'Analysis of covariance (ANCOVA) model included treatment as fixed effect, adjusted for baseline C3G histologic index activity score, disease type, and stratification factors.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline (Day 1) and Week 26', 'description': 'The C3G histologic index used to assess disease activity and chronicity in C3G. The C3G total activity score ranges from 0 (worse) to 21 (best). Higher scores indicate better outcome. Baseline was defined as the most recent non-missing measurement prior to taking the first dose of study drug.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITT analysis set included all randomized subjects. Since adolescents subjects were not required to provide post-screening biopsies, this endpoint was analyzed based on adult subjects only.'}, {'type': 'SECONDARY', 'title': 'Randomized Controlled Period: Percentage of Subjects Who Showed Decrease in C3c Staining on Renal Biopsy From Baseline at Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'OG000'}, {'value': '34', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'OG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}], 'classes': [{'categories': [{'measurements': [{'value': '74.29', 'groupId': 'OG000'}, {'value': '11.76', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '27.392', 'ciLowerLimit': '6.477', 'ciUpperLimit': '115.852', 'groupDescription': 'The logistic model included treatment group as independent variable and adjusted for baseline C3c staining, disease type, and stratification factors.', 'statisticalMethod': 'Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline (Day 1) and Week 26', 'description': 'Subject who showed decrease in C3c staining was defined as decrease of at least 2 orders of magnitude of intensity from baseline. Percentages are rounded off to the hundredth decimal place.', 'unitOfMeasure': 'percentage of subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITT analysis set included all randomized subjects. Since adolescents subjects were not required to provide post-screening biopsies, this endpoint was analyzed based on adult subjects only.'}, {'type': 'SECONDARY', 'title': 'Randomized Controlled Period: Change From Baseline in Estimated Glomerular Filtration Rate at Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'OG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.497', 'groupId': 'OG000', 'lowerLimit': '-5.892', 'upperLimit': '2.899'}, {'value': '-7.808', 'groupId': 'OG001', 'lowerLimit': '-11.570', 'upperLimit': '-4.047'}]}]}], 'analyses': [{'pValue': '0.0333', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in LS mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.312', 'ciLowerLimit': '0.501', 'ciUpperLimit': '12.122', 'groupDescription': 'An MMRM model included fixed categorical effect for treatment group, visit, disease type, stratification factors, and the visit-by-treatment group interactions as well as the continuous, fixed covariate of baseline eGFR, was utilized to analyze the mean change from baseline to Week 26 in eGFR.', 'statisticalMethod': 'MMRM', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline (Day 1) and Week 26', 'description': 'Serum samples were collected to determine the eGFR, calculated by using chronic kidney disease-epidemiology collaboration (CKD-EPI) creatinine equation for adults and the Bedside Schwartz equation for adolescents. Baseline eGFR value was calculated using the last non-missing assessment prior to first dose of study drug.', 'unitOfMeasure': 'milliliter (mL)/minute/1.73 m^2', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITT analysis set included all randomized subjects.'}, {'type': 'SECONDARY', 'title': 'Randomized Controlled Period: Percentage of Subjects Who Achieved Proteinuria <1 Gram (g)/Day at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'OG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}], 'classes': [{'categories': [{'measurements': [{'value': '36.51', 'groupId': 'OG000'}, {'value': '11.48', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.0006', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.753', 'ciLowerLimit': '2.106', 'ciUpperLimit': '15.716', 'groupDescription': 'The logistic model included treatment group as independent variable and adjusted for baseline proteinuria values, disease type, and stratification factors.', 'statisticalMethod': 'Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 24', 'description': 'Urine samples were collected to determine the proteinuria. Percentage of subjects who achieved proteinuria \\<1 g/day was assessed by 24-hour urine protein. Percentages are rounded off to the hundredth decimal place.', 'unitOfMeasure': 'percentage of subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITT analysis set included all randomized subjects.'}, {'type': 'SECONDARY', 'title': 'Randomized Controlled Period: Percentage of Subjects With Normalization of Serum Albumin Levels at Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'OG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}], 'classes': [{'categories': [{'measurements': [{'value': '77.78', 'groupId': 'OG000'}, {'value': '4.35', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '88.341', 'ciLowerLimit': '8.863', 'ciUpperLimit': '880.544', 'groupDescription': 'The logistic model included treatment group as independent variable and adjusted for baseline albumin values, disease type, and stratification factors.', 'statisticalMethod': 'Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 26', 'description': 'Baseline serum albumin value was calculated as the average of up to 2 serum albumin measurements preceding and including Day 1. Week 26 serum albumin values was calculated as the average of up to 2 serum albumin measurements preceding and including Week 26, no earlier than Week 20 measurement. Percentages are rounded off to the hundredth decimal place.', 'unitOfMeasure': 'percentage of subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITT analysis set included all randomized subjects. Only subjects with serum albumin levels below lower limit of normal (LLN) at baseline are analyzed.'}, {'type': 'SECONDARY', 'title': 'Randomized Controlled Period: Percentage of Subjects With Serum C3 Levels Above the Lower Limit of Normal at Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'OG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}], 'classes': [{'categories': [{'measurements': [{'value': '90.24', 'groupId': 'OG000'}, {'value': '6.12', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.0094', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '999.999', 'ciLowerLimit': '12.175', 'ciUpperLimit': '9999.999', 'groupDescription': 'The logistic model included treatment group as independent variable and adjusted for baseline C3 levels, stratification factors and disease type.', 'statisticalMethod': 'Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 26', 'description': 'Baseline serum C3 value was calculated as the average of up to 2 serum C3 measurements preceding and including Day 1. Week 26 serum C3 value was calculated as the average of up to 2 serum C3 measurements preceding and including Week 26, no earlier than Week 20 measurement. Percentages are rounded off to the hundredth decimal place.', 'unitOfMeasure': 'percentage of subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITT analysis set included all randomized subjects. Only subjects with serum C3 levels below LLN at baseline are analyzed.'}, {'type': 'SECONDARY', 'title': 'Randomized Controlled Period: Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'OG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.929', 'groupId': 'OG000', 'lowerLimit': '-1.549', 'upperLimit': '3.407'}, {'value': '0.367', 'groupId': 'OG001', 'lowerLimit': '-1.949', 'upperLimit': '2.683'}]}]}], 'analyses': [{'pValue': '0.7384', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in LS mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.562', 'ciLowerLimit': '-2.739', 'ciUpperLimit': '3.863', 'groupDescription': 'The ANCOVA model included treatment as fixed effect, adjusted for baseline, disease type, and stratification factors.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline (Day 1) and Week 26', 'description': 'The FACIT-Fatigue scale was a 13-item Likert scaled instrument that was self-administered by subjects. Subjects were presented with 13 statements and asked to indicate their responses as it applied to the past 7 days. The 5 possible responses were "not at all" (0), "a little bit" (1), "somewhat" (2), "quite a bit" (3) and "very much" (4). With 13 statements the total score has a range of 0 (worse health-related quality of life) to 52 (best health-related quality of life). Higher scores indicate better quality of life. Baseline was defined as the most recent non-missing measurement prior to taking the first dose of study drug.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITT analysis set included all randomized subjects.'}, {'type': 'SECONDARY', 'title': 'Randomized Controlled Period: Change From Baseline in the Kidney Disease Quality of Life (KDQOL) Score at Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'OG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.757', 'groupId': 'OG000', 'lowerLimit': '-2.385', 'upperLimit': '3.900'}, {'value': '-0.587', 'groupId': 'OG001', 'lowerLimit': '-3.847', 'upperLimit': '2.672'}]}]}], 'analyses': [{'pValue': '0.5648', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Difference in LS mean', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.345', 'ciLowerLimit': '-3.237', 'ciUpperLimit': '5.927', 'groupDescription': 'The ANCOVA model included treatment as fixed effect, adjusted for baseline, disease type, and stratification factors.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline (Day 1) and Week 26', 'description': 'The KDQOL score was constructed as the KDQOL-36 Summary Score (KSS) by averaging the 24 items from Burden of Kidney Disease, Symptoms and Problems of Kidney Disease, and Effects of Kidney Disease on scale ranging from 0 (worse health-related quality of life) to 100 (best health-related quality of life). Higher scores indicate better quality of life. Baseline was defined as the most recent non-missing measurement prior to taking the first dose of study drug.', 'unitOfMeasure': 'units on a scale', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITT analysis set included all randomized subjects.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kilogram (kg) received pegcetacoplan 1080 milligram (mg) subcutaneous (SC) infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'FG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}, {'id': 'FG002', 'title': 'Open-Label Period: Pegcetacoplan to Pegcetacoplan', 'description': 'All eligible adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg who received pegcetacoplan in RCP continued to receive pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in OLP.\n\nEligible adolescent subjects with body weight 35 to \\<50 kg who received pegcetacoplan in RCP continued to receive pegcetacoplan 810 mg SC infusion twice weekly for 26 weeks in OLP.\n\nEligible adolescent subjects with body weight 30 to \\<35 kg who received pegcetacoplan in RCP continued to receive pegcetacoplan 648 mg SC infusion twice weekly for 26 weeks in OLP.'}, {'id': 'FG003', 'title': 'Open-Label Period: Placebo to Pegcetacoplan', 'description': 'All eligible adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg who received placebo in RCP entered OLP to receive pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in OLP.\n\nEligible adolescent subjects with body weight 35 to \\<50 kg who received placebo in RCP entered OLP to receive pegcetacoplan 810 mg SC infusion twice weekly for 26 weeks in OLP.\n\nEligible adolescent subjects with body weight 30 to \\<35 kg who received placebo in RCP entered OLP to receive pegcetacoplan 648 mg SC infusion twice weekly for 26 weeks in OLP.'}], 'periods': [{'title': 'Randomized Controlled Period (26 Weeks)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '63'}, {'groupId': 'FG001', 'numSubjects': '61'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'comment': 'Completed RCP and enrolled into OLP.', 'achievements': [{'groupId': 'FG000', 'numSubjects': '61'}, {'groupId': 'FG001', 'numSubjects': '57'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Investigator or Medical Monitor Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Pregnancy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}]}, {'title': 'Open-Label Period (26 Weeks)', 'milestones': [{'type': 'STARTED', 'achievements': [{'comment': 'Eligible subjects entered OLP.', 'groupId': 'FG000', 'numSubjects': '0'}, {'comment': 'Eligible subjects entered OLP.', 'groupId': 'FG001', 'numSubjects': '0'}, {'comment': "Eligible subjects from 'Randomized Controlled Period: Pegcetacoplan' reporting group entered OLP.", 'groupId': 'FG002', 'numSubjects': '61'}, {'comment': "Eligible subjects from 'Randomized Controlled Period: Placebo' reporting group entered OLP.", 'groupId': 'FG003', 'numSubjects': '57'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '59'}, {'groupId': 'FG003', 'numSubjects': '55'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}]}, {'type': 'Investigator or Medical Monitor Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '1'}]}]}], 'recruitmentDetails': 'This Phase 3 randomized, placebo-controlled, double-blinded study was conducted in subjects with complement 3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) at 122 sites.', 'preAssignmentDetails': 'This study consisted of a screening period (10 weeks), 26-week randomized controlled period (RCP), followed by a 26-week open-label period (OLP) and follow-up period (8 weeks). Subjects were randomized to receive pegcetacoplan or placebo in a ratio of 1:1 in RCP. A total of 124 subjects were enrolled in this study.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'BG000'}, {'value': '61', 'groupId': 'BG001'}, {'value': '124', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Randomized Controlled Period: Pegcetacoplan', 'description': 'All adult subjects (regardless of weight) and adolescent subjects with body weight \\>=50 kg received pegcetacoplan 1080 mg SC infusion twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 35 to \\<50 kg received pegcetacoplan 648 mg for the first SC infusion and 810 mg SC infusion thereafter twice weekly for 26 weeks in RCP.\n\nAdolescent subjects with body weight 30 to \\<35 kg received pegcetacoplan 540 mg for the first 2 SC infusions and 648 mg SC infusion thereafter twice weekly for 26 weeks in RCP.'}, {'id': 'BG001', 'title': 'Randomized Controlled Period: Placebo', 'description': 'All adult subjects (regardless of weight) and adolescent subjects (with body weight: 30 to \\<35 kg, 35 to \\<50 kg, and \\>=50 kg) received placebo matching with pegcetacoplan SC infusion twice weekly for 26 weeks in RCP.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '28.2', 'spread': '17.08', 'groupId': 'BG000'}, {'value': '23.6', 'spread': '14.26', 'groupId': 'BG001'}, {'value': '26.0', 'spread': '15.86', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '37', 'groupId': 'BG000'}, {'value': '33', 'groupId': 'BG001'}, {'value': '70', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '26', 'groupId': 'BG000'}, {'value': '28', 'groupId': 'BG001'}, {'value': '54', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'categories': [{'title': 'American Indian or Alaskan Native', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '18', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '45', 'groupId': 'BG000'}, {'value': '46', 'groupId': 'BG001'}, {'value': '91', 'groupId': 'BG002'}]}, {'title': 'Other', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '13', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'categories': [{'title': 'Hispanic', 'measurements': [{'value': '15', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '41', 'groupId': 'BG000'}, {'value': '47', 'groupId': 'BG001'}, {'value': '88', 'groupId': 'BG002'}]}, {'title': 'Not Reported', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}]}, {'title': 'Unknown', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The intent-to-treat (ITT) analysis set included all randomized subjects.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2024-04-25', 'size': 1728030, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2025-06-26T16:21', 'hasProtocol': True}, {'date': '2025-02-10', 'size': 30447280, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2025-06-26T16:22', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 124}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-11-12', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-08', 'completionDateStruct': {'date': '2025-01-14', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-08-01', 'studyFirstSubmitDate': '2021-09-23', 'resultsFirstSubmitDate': '2025-06-26', 'studyFirstSubmitQcDate': '2021-09-23', 'lastUpdatePostDateStruct': {'date': '2025-08-06', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2025-08-01', 'studyFirstPostDateStruct': {'date': '2021-10-05', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-08-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-06-26', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Randomized Controlled Period: Change From Baseline in Log-Transformed Urine Protein-to-Creatinine Ratio (uPCR) at Week 26', 'timeFrame': 'Baseline (Day -70 to Day 1) to Week 26', 'description': 'Baseline uPCR value was calculated as the average of the uPCR measurements from at least 6 of the 9 first-morning spot urine (FMU) samples collected between the start of screening and Day 1, inclusive. The uPCR values used to calculate baseline included those from the samples collected on Day -2, Day -1, and before dosing on Day 1. In situations where less than 6 samples or more than 9 samples were collected, the average of all collected samples was used for baseline derivation. The difference between treatment groups using a composite contrast of equal-weighted average over Weeks 24, 25, and 26 was estimated.'}], 'secondaryOutcomes': [{'measure': 'Randomized Controlled Period: Percentage of Subjects Who Achieved the Composite Renal Endpoint at Week 26', 'timeFrame': 'Week 26', 'description': 'Subject who achieved a composite renal endpoint was defined as: (1) a stable or improved estimated glomerular filtration rate (eGFR) compared to baseline (\\<=15% reduction in eGFR), and (2) a \\>=50% reduction in uPCR compared to baseline. Percentages are rounded off to the hundredth decimal place.'}, {'measure': 'Randomized Controlled Period: Percentage of Subjects With a Reduction of At Least 50% From Baseline in Urine Protein-to-Creatinine Ratio at Week 26', 'timeFrame': 'Baseline (Day -70 to Day 1) and Week 26', 'description': 'Baseline uPCR value was calculated as the average of the uPCR measurements from at least 6 of the 9 FMU samples collected between the start of screening and Day 1, inclusive. The uPCR values used to calculate baseline included those from the samples collected on Day -2, Day -1, and before dosing on Day 1. In situations where less than 6 samples or more than 9 samples were collected, the average of all collected samples was used for baseline derivation. Percentages are rounded off to the hundredth decimal place.'}, {'measure': 'Randomized Controlled Period: Change From Baseline in the C3 Glomerulopathy (C3G) Histologic Index Activity Score at Week 26', 'timeFrame': 'Baseline (Day 1) and Week 26', 'description': 'The C3G histologic index used to assess disease activity and chronicity in C3G. The C3G total activity score ranges from 0 (worse) to 21 (best). Higher scores indicate better outcome. Baseline was defined as the most recent non-missing measurement prior to taking the first dose of study drug.'}, {'measure': 'Randomized Controlled Period: Percentage of Subjects Who Showed Decrease in C3c Staining on Renal Biopsy From Baseline at Week 26', 'timeFrame': 'Baseline (Day 1) and Week 26', 'description': 'Subject who showed decrease in C3c staining was defined as decrease of at least 2 orders of magnitude of intensity from baseline. Percentages are rounded off to the hundredth decimal place.'}, {'measure': 'Randomized Controlled Period: Change From Baseline in Estimated Glomerular Filtration Rate at Week 26', 'timeFrame': 'Baseline (Day 1) and Week 26', 'description': 'Serum samples were collected to determine the eGFR, calculated by using chronic kidney disease-epidemiology collaboration (CKD-EPI) creatinine equation for adults and the Bedside Schwartz equation for adolescents. Baseline eGFR value was calculated using the last non-missing assessment prior to first dose of study drug.'}, {'measure': 'Randomized Controlled Period: Percentage of Subjects Who Achieved Proteinuria <1 Gram (g)/Day at Week 24', 'timeFrame': 'Week 24', 'description': 'Urine samples were collected to determine the proteinuria. Percentage of subjects who achieved proteinuria \\<1 g/day was assessed by 24-hour urine protein. Percentages are rounded off to the hundredth decimal place.'}, {'measure': 'Randomized Controlled Period: Percentage of Subjects With Normalization of Serum Albumin Levels at Week 26', 'timeFrame': 'Week 26', 'description': 'Baseline serum albumin value was calculated as the average of up to 2 serum albumin measurements preceding and including Day 1. Week 26 serum albumin values was calculated as the average of up to 2 serum albumin measurements preceding and including Week 26, no earlier than Week 20 measurement. Percentages are rounded off to the hundredth decimal place.'}, {'measure': 'Randomized Controlled Period: Percentage of Subjects With Serum C3 Levels Above the Lower Limit of Normal at Week 26', 'timeFrame': 'Week 26', 'description': 'Baseline serum C3 value was calculated as the average of up to 2 serum C3 measurements preceding and including Day 1. Week 26 serum C3 value was calculated as the average of up to 2 serum C3 measurements preceding and including Week 26, no earlier than Week 20 measurement. Percentages are rounded off to the hundredth decimal place.'}, {'measure': 'Randomized Controlled Period: Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 26', 'timeFrame': 'Baseline (Day 1) and Week 26', 'description': 'The FACIT-Fatigue scale was a 13-item Likert scaled instrument that was self-administered by subjects. Subjects were presented with 13 statements and asked to indicate their responses as it applied to the past 7 days. The 5 possible responses were "not at all" (0), "a little bit" (1), "somewhat" (2), "quite a bit" (3) and "very much" (4). With 13 statements the total score has a range of 0 (worse health-related quality of life) to 52 (best health-related quality of life). Higher scores indicate better quality of life. Baseline was defined as the most recent non-missing measurement prior to taking the first dose of study drug.'}, {'measure': 'Randomized Controlled Period: Change From Baseline in the Kidney Disease Quality of Life (KDQOL) Score at Week 26', 'timeFrame': 'Baseline (Day 1) and Week 26', 'description': 'The KDQOL score was constructed as the KDQOL-36 Summary Score (KSS) by averaging the 24 items from Burden of Kidney Disease, Symptoms and Problems of Kidney Disease, and Effects of Kidney Disease on scale ranging from 0 (worse health-related quality of life) to 100 (best health-related quality of life). Higher scores indicate better quality of life. Baseline was defined as the most recent non-missing measurement prior to taking the first dose of study drug.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['C3G', 'IC-MPGN', 'C3 Glomerulopathy', 'C3 Glomerulonephritis', 'Complement 3 Glomerulopathy', 'Complement 3 Glomerulopathy (C3G)', 'Complement 3 Glomerulonephritis', 'Dense Deposit Disease', 'DDD', 'Membranoproliferative Glomerulonephritis', 'Membranoproliferative Glomerulonephritis (MPGN)', 'Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)']}, 'referencesModule': {'references': [{'pmid': '41337715', 'type': 'DERIVED', 'citation': 'Fakhouri F, Bomback AS, Ariceta G, Delmas Y, Dixon BP, Gale DP, Greenbaum LA, Han SH, Isbel N, Le Quintrec M, Licht C, Mastrangelo A, Mizuno M, Neves de Holanda MI, Pickering MC, Remuzzi G, Van De Kar N, Vivarelli M, Walker PD, Wallace D, Zecher D, Francois C, Deschatelets P, Li L, Wang Z, Abad-Franch L, Kinnman N, Lopez-Lazaro L, Szamosi J, Nester CM; VALIANT Trial Investigators Group. Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. N Engl J Med. 2025 Dec 4;393(22):2210-2220. doi: 10.1056/NEJMoa2501510.'}]}, 'descriptionModule': {'briefSummary': 'This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '12 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Aged at least 18 years; where approved, adolescents (aged 12-17 years) weighing at least 30 kg may also be enrolled.\n2. A diagnosis of primary C3G or IC-MPGN (with or without previous renal transplant).\n3. Evidence of active renal disease, based on one or more of the following:\n\n 1. In adults or adolescents with a baseline renal biopsy (either one collected during screening or a historic biopsy collected within 28 weeks prior to randomization), at least 2+ C3c staining on the baseline renal biopsy.\n 2. In adolescents not providing a baseline renal biopsy, at least one of the following:\n\n * Plasma sC5b-9 level above the upper limit of normal during screening\n * Serum C3 below the LLN during screening\n * Presence of an active urine sediment during screening, as evidenced by hematuria with at least 5 red blood cells (RBCs) per high-power field (HPF) and/or red blood cell casts on local or central microscopic analysis of urine.\n * Presence of C3 nephritic factor within 6 months of screening, based on central laboratory results or medical history.\n4. No more than 50% global glomerulosclerosis or interstitial fibrosis on the baseline biopsy for adult participants or adolescent participants providing a baseline biopsy.\n5. At least 1 g/day of proteinuria on a screening 24-hour urine collection and a uPCR of at least 1000 mg/g in at least 2 first-morning spot urine samples collected during screening.\n6. eGFR ≥30 mL/min/1.73 m2 calculated by the Chronic Kidney Disease-Epidemiology Collaboration creatinine equation for adults or the Bedside Schwartz equation for adolescents.\n7. Stable regimen for C3G/IC-MPGN treatment, as described below:\n\n 1. Angiotensin-converting enzyme inhibitor/, angiotensin receptor blocker, and/or sodium-glucose cotransporter-2 inhibitor therapy that is stable and optimized, in the opinion of the investigator, for at least 12 weeks prior to randomization\n 2. Stable doses of other medications that can affect proteinuria (eg, steroids, mycophenolate mofetil, and/or other allowed immunosuppressants that the participant is receiving for treatment of C3G or IC-MPGN) for at least 812 weeks prior to the baseline renal biopsy and randomization.\n 3. If a participant is on prednisone (or other systemic corticosteroid) for C3G or IC-MPGN treatment, the dosage is stable and no higher than 20 mg/day (or equivalent dosage of a corticosteroid other than prednisone) for at least 12 weeks prior to randomization.\n8. Have received vaccinations against S pneumoniae, N meningitidis (types A, C, W, Y, and B), and H influenzae (type B) within 5 years prior to randomization or agree to receive vaccinations during screening.\n\nExclusion Criteria:\n\n1. Previous exposure to pegcetacoplan.\n2. C3G/IC-MPGN secondary to another condition (eg, infection, malignancy, monoclonal gammopathy, a systemic autoimmune disease such as systemic lupus erythematosus, chronic antibody-mediated rejection, or a medication), in the opinion of the investigator.\n3. Current or prior diagnosis of human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) infection or positive serology during screening that is indicative of infection with any of these viruses.\n4. Body weight greater than 100 kg at screening.\n5. Hypersensitivity to pegcetacoplan or to any of the excipients.\n6. History of meningococcal disease.\n7. Malignancy, except for the following:\n\n 1. Cured basal or squamous cell skin cancer\n 2. Curatively treated in situ disease\n 3. Malignancy-free and off treatment for ≥5 years\n8. Severe infection (eg, requiring IV antibiotic therapy) within 14 days prior to the first dose of pegcetacoplan.\n9. An absolute neutrophil count \\<1000 cells/mm3 at screening.\n10. Use of rituximab, belimumab, or any approved or investigational anticomplement therapy other than pegcetacoplan within 5 half-lives of that product prior to the screening period.\n11. Female participants who are pregnant or who are currently breastfeeding and are unwilling to discontinue for the duration of the study and for at least 90 days after the final dose of study drug.\n12. Presence or suspicion of severe infection during the screening period (including but not limited to recurrent or chronic infections) that, in the opinion of the investigator, may place the participant at unacceptable risk by study participation.\n13. Known or suspected hereditary fructose intolerance.'}, 'identificationModule': {'nctId': 'NCT05067127', 'acronym': 'VALIANT', 'briefTitle': 'Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Apellis Pharmaceuticals, Inc.'}, 'officialTitle': 'A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis', 'orgStudyIdInfo': {'id': 'APL2-C3G-310'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Group 1: Pegcetacoplan administration', 'description': 'Subcutaneous infusion of 20mL (1080 mg), twice weekly (for adults or adolescents \\>50kg), and the three other weight-based doses either of 10mL (540mg), 12mL (648mg), or 15mL (810mg)', 'interventionNames': ['Drug: Pegcetacoplan']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Group 2: Placebo administration', 'description': 'Subcutaneous infusion of either 10mL, 12mL, 15mL, or 20mL, twice weekly', 'interventionNames': ['Other: Placebo']}], 'interventions': [{'name': 'Pegcetacoplan', 'type': 'DRUG', 'description': 'Complement (C3) Inhibitor', 'armGroupLabels': ['Group 1: Pegcetacoplan administration']}, {'name': 'Placebo', 'type': 'OTHER', 'description': 'Sterile solution of equal volume to active arm', 'armGroupLabels': ['Group 2: Placebo administration']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35294', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'University of Alabama at Birmingham', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '90022', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Academic Medical Research Institute', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90033', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Keck School of Medicine, University of Southern California', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90095', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Ronald Reagan UCLA Medical Center (01035)', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92868', 'city': 'Orange', 'state': 'California', 'country': 'United States', 'facility': 'UCI Center for Clinical Research', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'zip': '95817', 'city': 'Sacramento', 'state': 'California', 'country': 'United States', 'facility': 'UC Davis Medical Center (Transplant Research) (01016)', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'country': 'United States', 'facility': "Children's Hospital Colorado", 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '32610', 'city': 'Gainesville', 'state': 'Florida', 'country': 'United States', 'facility': 'University of Florida', 'geoPoint': {'lat': 29.65163, 'lon': -82.32483}}, {'zip': '30322', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Emory University School of Medicine', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '30342', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Fides Clinical Research, LLC (01042)', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Institute for Public Health and Medicine Northwestern University Northwestern University (01041)', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60523', 'city': 'Oak Brook', 'state': 'Illinois', 'country': 'United States', 'facility': 'NANIU Research Chicago (01040)', 'geoPoint': {'lat': 41.83281, 'lon': -87.92895}}, {'zip': '46804', 'city': 'Fort Wayne', 'state': 'Indiana', 'country': 'United States', 'facility': 'Nephrology Associates of Northern IL and Inn (01043)', 'geoPoint': {'lat': 41.1306, 'lon': -85.12886}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'country': 'United States', 'facility': 'The University of Iowa', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '02115', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': "Boston Children's Hospital (01013)", 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '01107', 'city': 'Springfield', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Renal and Transplant Associates of New England, PC', 'geoPoint': {'lat': 42.10148, 'lon': -72.58981}}, {'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'University of Michigan Medical Center', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '64102', 'city': 'Kansas City', 'state': 'Missouri', 'country': 'United States', 'facility': "Children's Mercy Hospital", 'geoPoint': {'lat': 39.09973, 'lon': -94.57857}}, {'zip': '07601', 'city': 'Hackensack', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Hackensack Meridian Health', 'geoPoint': {'lat': 40.88593, 'lon': -74.04347}}, {'zip': '11040', 'city': 'New Hyde Park', 'state': 'New York', 'country': 'United States', 'facility': 'Cohen Children Hospital', 'geoPoint': {'lat': 40.7351, 'lon': -73.68791}}, {'zip': '10032', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'CUIMC - Columbia Nephrology', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '43210', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'The Ohio State University Medical Center', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '97239', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Health & Science University (01038)', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '18017', 'city': 'Bethlehem', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Northeast Clinical Research Center, LLC', 'geoPoint': {'lat': 40.62593, 'lon': -75.37046}}, {'zip': '79902', 'city': 'El Paso', 'state': 'Texas', 'country': 'United States', 'facility': 'MedResearch Inc', 'geoPoint': {'lat': 31.75872, 'lon': -106.48693}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': "Texas Children's Hospital", 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '1629', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Hospital Universitario Austral', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'CPA X5016KEH', 'city': 'Córdoba', 'country': 'Argentina', 'facility': 'Hospital Privado-Universitario de Cordoba', 'geoPoint': {'lat': -31.40648, 'lon': -64.18853}}, {'zip': 'X5000', 'city': 'Córdoba', 'country': 'Argentina', 'facility': 'Clinica Privada Velez Sarsfield', 'geoPoint': {'lat': -31.40648, 'lon': -64.18853}}, {'zip': '2605', 'city': 'Garran', 'state': 'Australian Capital Territory', 'country': 'Australia', 'facility': 'Canberra Hospital - Renal Clinical Trials & Research Unit', 'geoPoint': {'lat': -35.34206, 'lon': 149.10846}}, {'zip': 'QLD 4102', 'city': 'Woolloongabba', 'state': 'Queensland', 'country': 'Australia', 'facility': 'Princess Alexandra Hospital', 'geoPoint': {'lat': -27.48855, 'lon': 153.03655}}, {'zip': 'VIC 3128', 'city': 'Box Hill', 'country': 'Australia', 'facility': 'Monash University', 'geoPoint': {'lat': -37.81887, 'lon': 145.12545}}, {'zip': 'VIC 3065', 'city': 'Fitzroy', 'country': 'Australia', 'facility': 'St. Vincents Melbourne', 'geoPoint': {'lat': -37.79839, 'lon': 144.97833}}, {'zip': 'QLD 4102', 'city': 'Woolloongabba', 'country': 'Australia', 'facility': 'Princess Alexandra Hospital', 'geoPoint': {'lat': -27.48855, 'lon': 153.03655}}, {'zip': '6020', 'city': 'Innsbruck', 'country': 'Austria', 'facility': 'Medical University Hospital Innsbruck (43004)', 'geoPoint': {'lat': 47.26266, 'lon': 11.39454}}, {'zip': 'A-1090', 'city': 'Vienna', 'country': 'Austria', 'facility': 'Medizinische Universität Wien', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'zip': '1070', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'Hopital Erasme HUB Service Pharmacie', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '2650', 'city': 'Edegem', 'country': 'Belgium', 'facility': 'University Hospital Antwerp (32004)', 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}}, {'zip': 'B-3000', 'city': 'Leuven', 'country': 'Belgium', 'facility': 'Catholic University of Leuven', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': 'B-4000', 'city': 'Liège', 'country': 'Belgium', 'facility': 'CHU Sart-Tilman', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'zip': 'B-4000', 'city': 'Liège', 'country': 'Belgium', 'facility': 'Clinical Trials CHU de Liège', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'zip': '30150-221', 'city': 'Belo Horizonte', 'state': 'Minas Gerais', 'country': 'Brazil', 'facility': 'Santa Casa de Misericordia de Belo Horizonte', 'geoPoint': {'lat': -19.92083, 'lon': -43.93778}}, {'zip': '36025-340', 'city': 'Juiz de Fora', 'state': 'Minas Gerais', 'country': 'Brazil', 'facility': 'Centro de Tratamento de Doencas Renais', 'geoPoint': {'lat': -21.76417, 'lon': -43.35028}}, {'zip': '90020-090', 'city': 'Porto Alegre', 'state': 'Rio Grande do Sul', 'country': 'Brazil', 'facility': 'Irmandade da Santa Casa de Misericordia de Porto Alegre', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}, {'zip': '18618-687', 'city': 'Botucatu', 'country': 'Brazil', 'facility': 'HC UNESP Botucatu', 'geoPoint': {'lat': -22.88583, 'lon': -48.445}}, {'zip': '60430-372', 'city': 'Fortaleza', 'country': 'Brazil', 'facility': 'Hospital Universitario Walter Cantidio', 'geoPoint': {'lat': -3.71722, 'lon': -38.54306}}, {'zip': '90020-090', 'city': 'Porto Alegre', 'country': 'Brazil', 'facility': 'Irmandade da Santa Casa de Misericordia de Porto Alegre', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}, {'zip': '90035-903', 'city': 'Porto Alegre', 'country': 'Brazil', 'facility': 'Hospital de Clinicas de Porto Alegre', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}, {'zip': '52010-095', 'city': 'Recife', 'country': 'Brazil', 'facility': 'Real Hospital Portuguas de Beneficancia em Pernambuco', 'geoPoint': {'lat': -8.05389, 'lon': -34.88111}}, {'zip': '14110-000', 'city': 'Ribeirão Preto', 'country': 'Brazil', 'facility': 'Hospital das Clinicas de Ribeirao Preto, Division of Nephrology', 'geoPoint': {'lat': -21.1775, 'lon': -47.81028}}, {'zip': '22211-225', 'city': 'Rio de Janeiro', 'country': 'Brazil', 'facility': 'Nefrologia I-Dor', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}, {'zip': '22270-060', 'city': 'Rio de Janeiro', 'country': 'Brazil', 'facility': 'Ruschel Medicina E Pesquisa Clinica', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}, {'zip': '150900-000', 'city': 'São José do Rio Preto', 'country': 'Brazil', 'facility': 'Hospital de Base', 'geoPoint': {'lat': -20.81972, 'lon': -49.37944}}, {'zip': '04038-002', 'city': 'São Paulo', 'country': 'Brazil', 'facility': 'UNIFESP - Hospital Sao Paulo', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '05403-000', 'city': 'São Paulo', 'country': 'Brazil', 'facility': 'Instituto da Crianca-Hospital das Clinicas University of Sao Paulo', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '05403-900', 'city': 'São Paulo', 'country': 'Brazil', 'facility': 'HCFMUSP-Hospital Clinicas da Faculdade Medicina da Universidade de São Paulo', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': 'M5G 1X8', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Hospital for Sick Children (11003)', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'QC H1T2M4', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Hopital Maisonneuve-Rosemont', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': '140 21', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Institute for Clinical and Experimental Medicine', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'Faculty Hospital Kralovske Vinohrady (42002)', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '33076', 'city': 'Bordeaux', 'country': 'France', 'facility': 'CHU de Bordeaux - Hopital Pellegrin', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'zip': '94010', 'city': 'Créteil', 'country': 'France', 'facility': 'Hopital Henri-Mondor', 'geoPoint': {'lat': 48.79266, 'lon': 2.46569}}, {'zip': '69437', 'city': 'Lyon', 'country': 'France', 'facility': 'Hospital Edouard Herriot, Hospices Civils de Lyon', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '34295', 'city': 'Montpellier', 'country': 'France', 'facility': 'CHU Montpellier, Hopital Lapeyronie', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'zip': '44093', 'city': 'Nantes', 'country': 'France', 'facility': 'Nantes University Hospital', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '59037', 'city': 'Paris', 'country': 'France', 'facility': 'Lille Regional University Hospital Center, Claude Huriez Hospital, Department of Nephrology', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75015', 'city': 'Paris', 'country': 'France', 'facility': 'Hopital Necker (33014)', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75015', 'city': 'Paris', 'country': 'France', 'facility': 'Hôpital Européen Georges-Pompidou', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '42055', 'city': 'Saint-Priest-en-Jarez', 'country': 'France', 'facility': 'CHU de Saint Etienne, Hospital Nord', 'geoPoint': {'lat': 45.4739, 'lon': 4.37678}}, {'zip': '67091', 'city': 'Strasbourg', 'country': 'France', 'facility': 'University Hospital Strasbourg', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'zip': '31059', 'city': 'Toulouse', 'country': 'France', 'facility': 'Rangueil Hospital-University Hospital Center (CHU) of Toulouse', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '10117', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Charite Universitatsmedizin (49007)', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': 'D-45147', 'city': 'Essen', 'country': 'Germany', 'facility': 'Universitatsklinikum Essen (AoR), Zentrum fur Kinder (49005)', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '30625', 'city': 'Hanover', 'country': 'Germany', 'facility': 'Medizinische Hochschule Hannover, Studienzentrum fur Nieren und Hochdruckerkrankungen', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'zip': '55131', 'city': 'Mainz', 'country': 'Germany', 'facility': 'Universitatsmedizin Mainz', 'geoPoint': {'lat': 49.98185, 'lon': 8.28008}}, {'zip': '48149', 'city': 'Münster', 'country': 'Germany', 'facility': 'Universitatsklinikum Munster', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'zip': '93053', 'city': 'Regensburg', 'country': 'Germany', 'facility': 'University Hospital Regensburg (49004)', 'geoPoint': {'lat': 49.01513, 'lon': 12.10161}}, {'zip': '3109601', 'city': 'Haifa', 'country': 'Israel', 'facility': 'Rambam Health Care Campus', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '4920235', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Institute of Pediatric Nephrology', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'zip': '70123', 'city': 'Bari', 'country': 'Italy', 'facility': 'Policlinico di Bari', 'geoPoint': {'lat': 41.12066, 'lon': 16.86982}}, {'zip': '40138', 'city': 'Bologna', 'country': 'Italy', 'facility': 'Policlinico Sant Orsola-Malpighi', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'zip': '16147', 'city': 'Genova', 'country': 'Italy', 'facility': 'IRCCS Istituto Giannina Gaslini (39012)', 'geoPoint': {'lat': 45.21604, 'lon': 11.87211}}, {'zip': '98125', 'city': 'Messina', 'country': 'Italy', 'facility': 'Universita degli Studi di Messina', 'geoPoint': {'lat': 38.19394, 'lon': 15.55256}}, {'zip': '20156', 'city': 'Milan', 'country': 'Italy', 'facility': 'Istituto di Ricerche Farmacologiche Mario Negri IRCCS', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '20162', 'city': 'Milan', 'country': 'Italy', 'facility': 'ASST Grande Ospedale Metropolitano Niguarda', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '35128', 'city': 'Padua', 'country': 'Italy', 'facility': 'Azienda Ospedaliera Universitaria di Padova (39011)', 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}, {'zip': '27100', 'city': 'Pavia', 'country': 'Italy', 'facility': 'Instituti Clinici Scientifici Maugeri SPA-IRCCS', 'geoPoint': {'lat': 45.19205, 'lon': 9.15917}}, {'zip': '00165', 'city': 'Rome', 'country': 'Italy', 'facility': 'Ospedale Pediatrico Bambino Gesu', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '466-8560', 'city': 'Nagoya', 'state': 'Aichi-ken', 'country': 'Japan', 'facility': 'Nagoya University Hospital (81003)', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'zip': '474-8710', 'city': 'Ōbu', 'state': 'Aichi-ken', 'country': 'Japan', 'facility': "Aichi Children's Health and Medical Center", 'geoPoint': {'lat': 35.01756, 'lon': 136.94947}}, {'zip': '371-8511', 'city': 'Maebashi', 'state': 'Gunma', 'country': 'Japan', 'facility': 'Gunma University Hospital (81006)', 'geoPoint': {'lat': 36.4, 'lon': 139.08333}}, {'zip': '9208650', 'city': 'Kanazawa', 'state': 'Ishikawa-ken', 'country': 'Japan', 'facility': 'NHO Kanazawa Medical Center', 'geoPoint': {'lat': 36.6, 'lon': 136.61667}}, {'zip': '852-8501', 'city': 'Nagasaki', 'state': 'Nagasaki', 'country': 'Japan', 'facility': 'Nagasaki University Hospital (81005)', 'geoPoint': {'lat': 32.75, 'lon': 129.88333}}, {'zip': '430-8558', 'city': 'Hamamatsu', 'state': 'Shizuoka', 'country': 'Japan', 'facility': 'Seirei Hamamatsu General Hospital (81004)', 'geoPoint': {'lat': 34.7, 'lon': 137.73333}}, {'zip': '530-8480', 'city': 'Osaka', 'country': 'Japan', 'facility': 'Kitano Hospital', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'zip': '181-8611', 'city': 'Tokyo', 'country': 'Japan', 'facility': 'Kyorin University Hospital (81009)', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'zip': '1105 AZ', 'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'Emma Kinderziekenhuis, Amsterdam UMC', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '9713 GZ', 'city': 'Groningen', 'country': 'Netherlands', 'facility': 'University Medical Center Groningen', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}, {'zip': '6500 HB', 'city': 'Nijmegen', 'country': 'Netherlands', 'facility': 'Radboud University Medical Center', 'geoPoint': {'lat': 51.8425, 'lon': 5.85278}}, {'zip': '90-153', 'city': 'Lodz', 'country': 'Poland', 'facility': 'Samodzielny Publiczny Zaklad Opieki Zdrowotnej Uniwersytecki Szpital Kliniczny Nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '92-213', 'city': 'Lodz', 'country': 'Poland', 'facility': 'SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '42601', 'city': 'Daegu', 'country': 'South Korea', 'facility': 'Keimyung University Dongsan Medical Center', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'zip': '03722', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Yonsei University College of Medicine, Sinchon Severance Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '3080', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital (82005)', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '03080', 'city': 'Soeul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 36.9168, 'lon': 126.7319}}, {'zip': '08025', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Fundació Puigvert', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08035', 'city': 'Barcelona', 'country': 'Spain', 'facility': "Hospital Universitari Vall D'Hebron", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08035', 'city': 'Barcelona', 'country': 'Spain', 'facility': "Hospital Universitario Materno-Infantil Vall d' Hebron, Nefrologia Pediatrica", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08950', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Materno Infantil Sant Joan de Deu', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28041', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario 12 de Octubre, Nephrology Department', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '39008', 'city': 'Santander', 'country': 'Spain', 'facility': 'Hospital Universitario Marques de Valdecilla', 'geoPoint': {'lat': 43.46589, 'lon': -3.80493}}, {'zip': '41013', 'city': 'Seville', 'country': 'Spain', 'facility': 'University Hospital of Virgen del Rocio', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '46017', 'city': 'Valencia', 'country': 'Spain', 'facility': 'Hospital Universitario Dr Peset', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': 'CH-3010', 'city': 'Bern', 'country': 'Switzerland', 'facility': 'Inselspital, Bern University Hospital', 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}, {'zip': 'CH-1011', 'city': 'Lausanne', 'country': 'Switzerland', 'facility': 'CHUV Lausanne', 'geoPoint': {'lat': 46.516, 'lon': 6.63282}}, {'zip': 'CH-8091', 'city': 'Zurich', 'country': 'Switzerland', 'facility': 'Universitatsspital Zurich', 'geoPoint': {'lat': 47.36667, 'lon': 8.55}}, {'zip': 'GL1 3NN', 'city': 'Gloucester', 'country': 'United Kingdom', 'facility': 'Gloucestershire Hospitals NHS Foundation Trust', 'geoPoint': {'lat': 51.86568, 'lon': -2.2431}}, {'zip': 'LE1 5WW', 'city': 'Leicester', 'country': 'United Kingdom', 'facility': 'University Hospitals of Leicester NHS trust (44003)', 'geoPoint': {'lat': 52.6386, 'lon': -1.13169}}, {'zip': 'NW3 2QG', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Royal Free London NHS Foundation Trust (44015)', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SE1 7EH', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Evelina London Children Hospital (44016)', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SW17 0QT', 'city': 'London', 'country': 'United Kingdom', 'facility': "St George'Äôs University Hospitals NHS Foundation Trust (44014)", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'W12 0HS', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Imperial College Healthcare NHS Trust', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'WC1N 3JH', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Great Ormond Street Hospital Foundation Trust', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'M13 9WL', 'city': 'Manchester', 'country': 'United Kingdom', 'facility': "Royal Manchester Children's Hospital", 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'NG7 2UH', 'city': 'Nottingham', 'country': 'United Kingdom', 'facility': "Nottingham Children's Hospital", 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Apellis Pharmaceuticals, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}